The current review highlights the varied effects of medical foods high in leucine (Leu) and devoid of valine (Val) and isoleucine (Ile) in the management of methylmalonic acidemia (MMA) and propionic acidemia and cobalamin C (cblC) deficiency, aiming to advance dietary practices.
INTRODUCTION
The inborn errors of metabolism (IEM) are a heterogeneous group of disorders caused by defective enzymes and/or cofactors that facilitate the metabolism of fats, carbohydrates, or proteins. Typically, a deficiency or block at an important step of a metabolic pathway results in the buildup of toxic precursors and/or a deficiency of downstream metabolites. Most IEMs follow an autosomal recessive inheritance pattern, present in childhood and are accompanied by significant morbidity and mortality.
Propionic acidemia and methylmalonic acidemia (MMA) are rare, autosomal recessive organic acidemias characterized by enzymatic blocks in the degradation pathways of valine (Val), isoleucine (Ile), methionine (Met), and threonine (Thr), oddchain fats, and cholesterol [1, 2] . In propionic acidemia, there is a deficiency of the propionylCoA carboxylase enzyme, which converts propionyl-CoA to methylmalonyl-CoA [2] . Livebirth incidence of propionic acidemia is 1 : 105 000-1 : 130 000 in the United States [2] . Isolated MMA results from a defect in methylmalonylCoA mutase (mut 0 , mut À ) (which converts methylmalonyl-CoA to succinyl-CoA), the synthesis of the coenzyme 5 0 -deoxyadenosylcobalamin (cblA, cblB, cblD variant 2), or a deficiency of methylmalonylCoA epimerase [1] . Birth incidence ranges from 1 : 50 000 to 1 : 100 000 [1] . Neonatal onset is characterized by potentially fatal progressive encephalopathy that may present as lethargy, seizures, or coma [1, 2] . Long-term effects may include growth failure, intellectual disability, seizures, basal ganglia lesions, pancreatitis, cardiomyopathy, tubulointerstitial nephritis with progressive renal failure, immune dysfunction, and optic nerve atrophy [1, 2] .
In contrast to isolated MMA, cobalamin C (cblC) deficiency causes combined MMA and homocystinuria that results from a defect in 5 0 -deoxyadenosylcobalamin (the cofactor for methylmalonyl-CoA mutase) and methylcobalamin (the cofactor for Met synthase, which catalyzes methylation of homocysteine to form Met) [3] .
Patients with cblC deficiency typically present with failure to thrive, neurologic findings including seizures, global developmental delay, hemolytic uremic syndrome, cardiopulmonary manifestations, and vision loss due to a severe, progressive retinopathy and maculopathy [3] .
IEM's are managed uniquely, but in many cases, one of the core therapies includes some form of dietary restriction specific to the disorder, and use of medical foods. A medical food, as defined by the Food and Drug Administration in section 5(b) [3] of the Orphan Drug Act [21 U.S.C. 360ee (b) [3] ], is 'a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation' [4] . Medical foods for IEM's contain little to no precursors of the 'toxic' dietary precursors and supply essential nutrients that may be inadequately provided by a therapeutic diet restriction.
Leucine (Leu), an additive to many MMA/ propionic acidemia medical foods, has multiple metabolic effects, including modulation of branched-chain amino acid (BCAA) oxidation and transport of large neutral amino acids across the blood-brain barrier (BBB) [5, 6] . Medical foods for MMA and propionic acidemia contain normal-tohigh amounts of Leu and contain trace-to-no amino acid precursors metabolized by the defective enzymatic pathway, including Val, Ile, Met, and Thr. The use of medical foods in these disorders results in chronic and unbalanced Leu supplementation compared with the other BCAAs, and overuse can induce unintended effects on amino acid metabolism and transport [7 & ].
IMBALANCE OF BRANCHED-CHAIN AMINO ACIDS IN MEDICAL FOODS USED FOR METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA
Although Val and Ile degradation contributes to the accumulation of toxic metabolites in MMA and propionic acidemia, Leu oxidation diverges from the early shared committed step of the pathway after the branched-chain alpha-ketoacid dehydrogenase enzyme complex (BCKDH) step and is unaffected in MMA and propionic acidemia.
Similar to the approach used in the dietary management of other IEM's, medical foods developed for use in MMA and propionic acidemia were formulated with minimal-to-no propiogenic precursors (Val, Ile, Met, and Thr) but with regular content of nonoffensive amino acids, including Leu, to help meet overall protein needs. Medical foods currently on the market are composed of Leu: protein ratios approximately 1.1-1.9 times higher than the average ratio found in protein-rich foods such as cow's milk, chicken, beef, and eggs. A dose of medical food amino acids equal to or greater than complete protein intake, results in an imbalance of Leu intake compared with the other BCAA's, Met, and Thr. The Leu content of MMA/propionic acidemia medical foods, in the setting of absent/trace Val and Ile, renders these the only food products with an unbalanced BCAA composition.
METABOLIC EFFECTS OF A LEUCINE LOAD
Leu loads and Leu-enhanced diets have been extensively studied in humans and animals and found to have many regulatory functions (Fig. 1) . The roles of Leu include stimulation of insulin secretion and protein synthesis, as well as inhibition of protein degradation [5, 8] . Recent studies have contributed
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further evidence to support Leu's regulatory functions. Leu supplementation or a Leu-supplemented diet may mitigate the growth hormone (GH) resistance induced by severe protein-energy malnutrition in rats during protein repletion through enhanced synthesis of insulin-like growth factor 1 [9] , prevent low-dietary protein-induced hepatic steatosis in mice [10] , improve hepatic mitochondrial biogenesis and energy metabolism in weaning piglets [11] , function as a nitrogen donor to glutamate, which serves as the major excitatory neurotransmitter in the brain [12] , and stimulate mammalian target of rapamycin, which has many important brain functions [12] . Whether such Leu effects would be of benefit in MMA and propionic acidemia is yet to be determined, and the dietary Val and Ile restriction experienced by most patients might limit beneficial Leu effects.
While there are described benefits of Leu supplementation, excess Leu intake is linked to effects that could be potentially detrimental in MMA and propionic acidemia. For one, Leu signals the hypothalamus to modulate appetite suppression and decreases energy intake [5, 8, [12] [13] [14] , which is an undesirable effect in a disease in which poor feeding and growth failure are common. Moreover, short-term, high doses of Leu, over 500 mg/kg/day in healthy adults, causes an increase in blood ammonia levels, an effect that could be consequential in MMA and propionic acidemia patients who are at high risk for hyperammonemia [15 & ]. In addition, the Leu load delivered from medical foods designed for patients with MMA and propionic acidemia may alter Val, Ile, and Met plasma levels, transport, and metabolism. It has been well described that an oral or intravenous Leu load lowers plasma concentrations of the other two BCAAs [5] . As discussed by Manoli et al. [7 & ], decreased plasma levels of Val and Ile in response to an oral Leu load in fasting children were initially documented by Nyhan et al. in 1961, and the decreased plasma Val and Ile levels were not accounted for by increased urinary excretion. This same effect was observed after intravenous administration of Leu, which rules out a competitive inhibition effect of Leu on intestinal absorption of Val and Ile as the primary mechanism [5] . A more recent study has demonstrated that an oral Leu dose as low as 10-20 mg/kg body weight significantly lowered plasma concentrations of Val, Ile, and Phe in five healthy men who fasted overnight and then ate rice 1 h prior to Leu dosing [16] . Leu doses up to 90 mg/kg body weight also induced nonsignificant decreases of Met and tyrosine (Tyr) [16] . Importantly, an oral Leu load or Leu-enriched diet not only affects circulating Val and Ile levels, but was shown to decrease levels of Val and Ile in cardiac tissue in mice [17] and in skeletal muscle in rats [18] . The understanding of the mechanisms for these secondary effects of Leu on other amino acid plasma levels has been recently explored. A Leu load provided to fasted mice induced significant decreases in plasma levels of Val, Ile, Met, Phe, and Tyr [19] which were blunted when the system L amino acid transporter (LAT), a plasma membrane transporter, was blocked [19] . This suggests the LAT may mediate plasma amino acid changes [19] . Interestingly, a decrease in plasma levels of these amino acids lags after Leu levels peak, suggesting that intracellular concentration of Leu may have more important regulatory effects on LAT than do plasma levels [19] .
Other intermediary effects on the oxidation of BCAA, mediated by the BCKDH reaction, are also possible. BCKDH catalyzes the oxidation of the BCAA ketoacids and is inactivated by phosphorylation by BCKDH kinase [5] . The ketoacid of Leu, alpha-ketoisocaproate, protects BCKDH from inactivation through inhibition of BCKDH kinase (Fig. 1) [5] . Wessels et al. [20] examined changes in BCKDH activity and levels of amino acids in plasma and tissue in piglets fed a diet 2.3 or 3.3 times higher in Leu than control diets. On the highest Leu diet, BCKDH activity significantly increased in kidney, liver, cardiac muscle, and brain, leading to increased oxidation of all three BCAAs [20] . Both high-Leu diets decreased the concentrations of Val and Ile in plasma and in all tissues analyzed except for the duodenal mucosa [20] . Furthermore, Val, Ile, Met, Alanine (Ala), and Tryptophan (Trp) levels were significantly lower in the brain in response to the highest Leu diet [20] . The competition that takes place at the large neutral amino acid transporter (LAT1), which transports large neutral amino acids across the BBB [6] , may explain the effects of Leu on cerebral levels of these amino acids. Leu has a low K m for LAT1 and at higher concentrations, Leu inhibits the transport into the brain of other large neutral amino acids, including Val, Ile, Met, Thr, Phe, Tyr, Trp, histidine, and glutamine ( Fig. 1) [6] .
EFFECTS OF A LEUCINE LOAD FROM MEDICAL FOODS IN METHYLMALONIC ACIDEMIA, PROPIONIC ACIDEMIA, AND COBALAMIN C DEFICIENCY
Several of the Leu-induced effects described were evident in a cohort of 51 patients with isolated MMA (37 mut MMA) recently studied at NIH [7 & ].
These patients were drawn from diverse US and international metabolic centers and were treated using a broad range of dietary protocols. Medical food was used in the management of 85% of the mut MMA patients [7 & ]. In the youngest cohort, total intakes of Leu were 222 AE 24.9 mg/kg/day (range: 60-510 mg/kg/day) or four to five times the recommended requirement and well above the single-dose amount shown to decrease plasma Val and Ile levels in healthy men [7 & ,16] . Leu intake at the high end of this range surpassed levels associated with hyperammonemia in healthy adults and the proposed tolerable upper limit for adults [15 & ]. It should be noted that 35% of the mut subset were consuming more medical food protein equivalent than complete protein [7 & ]. Medical food use was associated with significantly increased plasma ratios of Leu : Val and Leu : Ile and decreased plasma concentrations of Val, Ile (as well as Met and Thr), even in those consuming complete protein at a level above the recommended dietary allowance (RDA). Because of the abnormal amino acid concentrations, seven mut patients were prescribed supplemental Val and/ or Ile (propiogenic and therefore toxic amino acids for MMA and propionic acidemia patients) to correct chronically low plasma levels, a counterintuitive practice in the management of this disorder [7 & ]. A case study presented by the authors demonstrated that by reducing medical food intake in a patient with low blood concentrations of Val and Ile, BCAA homeostasis was restored, and supplemental amino acid intake could be eliminated.
In addition, in the mut cohort, there was a significant cross-sectional correlation between the Leu: Val intake ratio and poorer growth outcome in terms of height, weight, and bone mineral density [7 & ]. These observations suggest that in the setting of a protein restriction, medical foods, via Leu effects, could increase the Val and Ile requirements by increasing BCAA oxidation and thereby negatively impact growth [5] . Evans et al. [21 & ] recently reported longitudinal growth data in an Australian cohort of 14 MMA/propionic acidemia patients. Significantly, better growth outcomes were seen in the Australian cohort for which medical foods were rarely used as compared with the largely US cohort in which medical food use was common [7 & ,21 & ]. Of course, an exact comparison cannot be made between the two studies without detailed phenotypic and metabolic characterization to define the disease severity of the respective patients. Furthermore, renal function, the GH axis, and periods of metabolic acidosis are additional variables likely to have strong effects on growth out-
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and thus, the stimulation by Leu of BCAA degradation may be appropriate to aid in metabolizing the dietary BCAA load. However, the stimulation of BCKDH by high Leu levels in MMA and propionic acidemia medical foods when Val and Ile intakes are restricted, exacerbates their deficiency, potentially adversely impacting growth.
Given that a Leu load at levels provided in routine use of medical foods could induce such effects, there may be additional perturbations that were not measured in the current studies. For example, as demonstrated by Wessels et al. [20] , brain levels of Val, Ile, Met, Ala, and Trp potentially could be reduced on a high Leu diet, resulting in cerebral essential amino acid deficiencies. Such effects could have disparate consequences depending on the stage of body and brain growth. Although essential amino acid deficiency in brain is detrimental during early development, inhibited brain uptake of Val and Ile could be protective of acute elevations of BCAA and toxic precursors in MMA and propionic acidemia once brain growth is complete as a means to neuroprotect the central nervous system. The effects of amino acid imbalances on other transporters and in other tissues, such as kidney, gastrointestinal system, and pancreas have yet to be explored. Furthermore, in addition to amino acid effects, future studies should explore the role of high nitrogen load from medical food supplementation on the risk for hyperammonemia and the progression of kidney disease of MMA, and possibly propionic acidemia. Additional studies are required to optimize the current evidence-based guidelines for age-appropriate prescription of medical foods for these patients.
In cblC deficiency, the propionate-derived metabolic disturbances are less marked than in isolated MMA and parenteral hydroxocobalamin treatment can greatly reduce methylmalonic acid levels. However, in practice, protein restriction and/or medical foods are sometimes prescribed as a means to control the methylmalonic acid levels. Manoli et al. [22 & ] reported that in a cohort of 28 patients with cblC deficiency, 21% received complete protein intake less than 85% of the RDA, and approximately 32% were taking medical foods designed for MMA and propionic acidemia. Reported elsewhere, medical food was used in 67% of patients in a small cohort of cblC deficiency [23 ] . Met synthesis is inhibited in cblC deficiency. Therefore, knowing that Leu may decrease plasma Met levels and the predicted brain uptake of Met through competitive inhibition at the LAT1 transporter [6, 20] ] also found a correlation between long-term medical food consumption and poor head circumference, though causation could not be assigned in either study. As cerebral synthesis of Met is impaired in cblC deficiency, there is an increased reliance on brain uptake of Met. Met has many important functions in the brain and inadequate cerebral Met levels may be responsible, in part, for brain white matter hypomyelination occasionally observed in cblC deficiency [22 & ]. Therefore, given that adequate brain uptake of Met is vital in this population, it is critical that future research investigates whether cerebral Met deficiency occurs with high Leu supplementation, even in the context of normal plasma levels of Met.
CONCLUSION
In summary, MMA, propionic acidemia, and cblC deficiency present disorders in which some of the normal regulatory functions of Leu may result in unintended consequences in the setting of an imbalanced BCAA diet induced by excessive medical food intake. Decreased plasma levels and a predicted reduction in brain uptake of Val, Ile, and Met could result from Val, Ile, and Met restriction when a patient ingests relative high doses of Leu via MMA/propionic acidemia medical foods. Further research is warranted to determine the optimal relative ratios of supplemental amino acids in these disorders and whether supplemental Leu may serve a beneficial role by limiting uptake of propiogenic amino acids into the brain and peripheral organs and delaying or attenuating long-term complications of the disease.
Recent dietary guidelines are supporting a lower reliance on medical foods in MMA and propionic acidemia. The 2014 European guidelines for management of MMA and propionic acidemia recommend that in situations where natural protein intolerance precludes protein intake at the Food and Agriculture Organization of the United Nations/WHO/United Nations University safe levels of intake, medical foods should be provided to help meet protein requirements, but the guidelines do Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
not recommend routine medical food use otherwise [24] . In 2017, the Genetic Metabolic Dietitian International released revised dietary guidelines for propionic acidemia [25] recommending that in patients who tolerate less than 100% of the daily protein requirement from complete protein, propionic acidemia medical food should be added to meet 100-120% of the total protein requirement [25] . This represents a significant reduction in medical food use from previous guidelines. Finally, 2017 European guidelines for cblC deficiency clearly state that Met-free formulas are contraindicated in cblC deficiency [26] .
Medical foods are critical for the dietary therapy of many IEM's, but many questions about their optimal composition and effectiveness in patients with disorders of propionate oxidation, such as MMA and propionic acidemia, remain unanswered. Until future research elucidates optimal medical food formulations for patients with MMA and propionic acidemia, the prescription of large amounts of medical foods relative to complete protein should be avoided. Furthermore, the current MMA/propionic acidemia medical foods are contraindicated in patients with cblC deficiency.
